Bandi Linea A

DA_DES

Digital and Sustainable Advanced Diagnostic
Eco healthcare
Spoke5_DA_DESimage
Scheda del progetto
Data
Start date
Valore
Total value
€ 432.492,50
Durata
Duration
18 months
Investimento
Investment nodes
€ 274.344,71

The DA_DES project aims to promote and realize the digital and sustainable transition of imaging diagnostics based on instrumental techniques (magnetic resonance, TAC, ultrasound, scintigraphy, etc..) and dedicated probes. 

DA_DES involves the collaboration between Bracco Imaging which will handle the scale-up preparation and characterization of contrast agents, as well as the design and development of digital procedures to optimize their usem and CAGE Chemicals that will contribute with innovative and sustainable synthetic approaches to obtain the necessary chemical compounds for their preparation. 

The collaboration with three research organizations (UPO, UNiPV, Policlinico San Matteo) will ensure specialized expertise, the solutions identified in the preclinical field can have a rapid application in the clinical field. 

 

Contact:

Francesco Blasi 

francesco.blasi@bracco.com

The goal
Document

The project aims to optimize the sustaibability of contrast agents by developing new diagnostic pharmaceutical products together with innovative digital solutions that are sustainable and environmentally neutral.  

This includes three main objectives: replacing gadolinium with iron, using artificial intelligence to reduce the amount of contrast agent and implementing innovative packaging to improve supply chain sustainability.  

 

Why is it innovative
Document

The innovativeness of DA_DES lies in its strong digital component, which includes the use of artificial intelligence and machine learning to guide diagnosis and support therapeutic decisions, as well as the analysis of big data to improve internal diagnostic management processes. 

Impact on the users
Document

The project stands out for integrating pharmaceutical products and sustainable digital solutions to contribute to early diagnosis in order to stop or slow the development of diseases contributing both to improve the quality of life of patients and to alleviate their impact on healthcare services.  

The optimization of contrast agents will have a significant impact on the sector, reducing CO2 emissions and improving economic efficiency as well.